Adenoid Cystic Carcinoma Pipeline Analysis 2019 (H1)

Report
79 Pages
May 2019
Region: Global
Knowledge Sourcing Intelligence LLP
ID: 4801724

Adenoid Cystic Carcinoma Pipeline Analysis report covers more than 10 drugs currently in different phases of development. Adenoid cystic carcinoma (ACC) is a rare form of adenocarcinoma which occurs in the secretory glands, most common ones include the major and minor salivary glands of neck and head. It can occur in other locations of the body as well. This is due to the reason that the carcinoma travels through nerves and may lead to pain or nerve paralysis. The exact cause of ACC is however unknown and is not caused by the inheritance. Treatment includes chemotherapy, radiation or surgery depending on the condition of the patient.

The report provides Adenoid Cystic Carcinoma treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the market.

Major industry players profiled as part of the report are Merck Sharp & Dohme Corp., Lilly USA, LLC, Beigene Corporation and Eisai Inc. among others.

Scope:

By Company
By Phase
By Molecule Type
By Region
By Route of Administration

1. Introduction

1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region

2. Disease Overview

2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology

3. Executive Summary

4. Market Dynamics

4.1. Drivers
4.2. Restraints
4.3. Opportunities

5. Pipeline Analysis/Outlook

5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling

Drug Name
Generic Name
Synonyms
Company
Collaborator
Route of administration
Target
Mechanism of Action
Technology
Molecule type
CAS Number
Weight
Chemical Formula
IUPAC name
ATC code

5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region

6. Company profiling

6.1. Merck & Co., Inc.
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.1.5. Recent Development
6.2. Bayer AG
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.2.5. Recent Development
6.3. Novartis AG
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.3.5. Recent Development
6.4. Bristol-Myers Squibb
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.4.5. Recent Development
6.5. Ipsen
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.5.5. Recent Development
6.6. Ayala Pharmaceuticals, Inc.
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.6.5. Recent Development
6.7. Eisai Co., Ltd.
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.7.5. Recent Development
6.8. Pfizer
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.8.5. Recent Development
6.9. CureVac AG
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.9.5. Recent Development
6.10. Cellestia Biotech AG
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.10.5. Recent Development
6.11. Amgen Inc.
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.11.5. Recent Development
6.12. BeiGene
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
6.12.5. Recent Development
6.13. Boston Biomedical
6.13.1. Introduction
6.13.2. Financials
6.13.3. Products and Services
6.13.4. SWOT
6.13.5. Recent Development
6.14. Oncology Venture
6.14.1. Introduction
6.14.2. Financials
6.14.3. Products and Services
6.14.4. SWOT
6.14.5. Recent Development
6.15. Syndax
6.15.1. Introduction
6.15.2. Financials
6.15.3. Products and Services
6.15.4. SWOT
6.15.5. Recent Development

Companies Mentioned

Merck & Co., Inc.
Bayer AG
Novartis AG
Bristol-Myers Squibb
Ipsen
Ayala Pharmaceuticals, Inc.
Eisai Co., Ltd.
Pfizer
CureVac AG
Cellestia Biotech AG
Amgen Inc.
BeiGene
Boston Biomedical
Oncology Venture
Syndax

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€2829EUR$2,900USD£2,415GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€5755EUR$5,900USD£4,914GBP

Table of Contents

Companies Mentioned

Methodology

Related Topics

Related Reports

Adenoid Cystic Carcinoma Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

Hepatocellular Carcinoma Drugs Global Market Report 2024

Neuroendocrine Carcinoma Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Market Participants, Regions, Technology, Application, Product Type

Hepatocellular Carcinoma Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

Adenoid Cystic Carcinoma - Market Insight, Epidemiology and Market Forecast - 2032